The SAB-142 FDA Fast Track designation gives an experimental type 1 diabetes immunotherapy a faster path for regulatory interaction, but it does not show that the drug works. On 13 October 2026, SAB Biotherapeutics announced that the US Food and Drug Administration had granted Fast Track status to SAB-142 for new-onset Stage 3 type 1 diabetes, the stage at which the disease is clinically diagnosed. The company, based in Miami and listed on Nasdaq as SABS, calls the drug a potentially disease-modifying immunotherapy.
The aim of such a therapy would be to slow the immune attack on insulin-producing cells, not to replace insulin. Nothing has been approved yet. This article explains what SAB-142 is, what trials are under way and what the designation does and does not mean.
Key takeaways
- The FDA granted Fast Track designation to SAB-142 for new-onset Stage 3 type 1 diabetes.
- SAB-142 is described as a fully human anti-thymocyte immunoglobulin made in transchromosomic cattle.
- A registrational Phase 2b trial, SAFEGUARD, expects to finish enrolment in the fourth quarter of 2026, with topline data in the second half of 2027.
- A separate investigator-led Phase 3 trial, PRISE-hATG, will test people up to two years after diagnosis.
- Fast Track is not approval and says nothing about efficacy.
What the SAB-142 FDA Fast Track designation means
The FDA grants Fast Track to drugs that treat serious conditions and address an unmet medical need, with the aim of facilitating development and speeding review. Benefits typically include more frequent communication with the agency and the chance for a rolling review of an application. The status is based on the potential to address a need, not on proof that the drug meets it, and many Fast Track drugs fail in later trials.
The company’s announcement does not mention earlier FDA designations for SAB-142. Chief executive Samuel J. Reich called the decision an important regulatory milestone and said it represents meaningful progress toward bringing the treatment to people with type 1 diabetes as quickly as possible.
Stage 3 type 1 diabetes and the SAB-142 FDA Fast Track designation
Type 1 diabetes is an autoimmune disease in which the immune system destroys the beta cells in the pancreas that make insulin. The National Institute of Diabetes and Digestive and Kidney Diseases describes it as a condition that needs lifelong insulin treatment. Researchers divide the disease into stages: Stage 1 and 2 have immune markers and, in Stage 2, abnormal blood sugar without symptoms, while Stage 3 is the point of clinical diagnosis, when symptoms appear.
At diagnosis many people still have some beta-cell function. Preserving it can make blood sugar easier to manage and may lower the risk of complications. That is the logic behind immune-modulating drugs in new-onset disease. For context, an antibody called teplizumab is already approved in the United States to delay the onset of Stage 3 disease in people at Stage 2. SAB-142 is aimed at people who already have Stage 3.
What is SAB-142?
SAB Biotherapeutics describes itself as developing a fully human anti-thymocyte immunoglobulin, abbreviated hATG. Anti-thymocyte globulins are antibody preparations that reduce certain immune cells, and animal-derived versions are used in transplant medicine. The company produces its antibodies in transchromosomic cattle, called Tc-Bovine, which make human immunoglobulin G. It says the platform does not require human donors or convalescent plasma.
Earlier research with animal-derived anti-thymocyte globulin in recent-onset type 1 diabetes has been reported, but those studies used a different product, and their results cannot be assumed to apply to SAB-142. The release does not present efficacy or safety data for SAB-142 in patients.
The trials behind the SAB-142 FDA Fast Track designation
- SAFEGUARD: a registrational Phase 2b trial enrolling people within 100 days of a Stage 3 diagnosis. Enrolment is expected to complete in the fourth quarter of 2026, with topline data anticipated in the second half of 2027.
- PRISE-hATG: an investigator-led Phase 3 trial evaluating SAB-142 in people with Stage 3 disease from 100 days to two years after diagnosis.
The company calls SAFEGUARD registrational, which means it is designed to support a regulatory filing if the results are strong. The release does not state the endpoints, doses or number of participants. Trials in new-onset diabetes usually measure preservation of C-peptide, a marker of the body’s own insulin production, alongside safety, but we cannot confirm that for these studies. Details should appear in the registry entry at ClinicalTrials.gov.
Safety questions to watch
Drugs that suppress parts of the immune system can raise the risk of infection, infusion reactions and other effects. The announcement does not describe SAB-142’s safety profile in people. That will be central to the trials, since type 1 diabetes often begins in children and young adults who would need to take on that risk for a chance of preserving beta-cell function.
For related diabetes coverage, see our report on Temple University and Aide Health’s AI diabetes management model and our report on Medtronic’s Simplera Sync sensor launch in South Korea, or browse our pharmaceutical coverage.
Our assessment of the SAB-142 FDA Fast Track designation
In our assessment, the SAB-142 FDA Fast Track designation is a helpful but modest milestone. It confirms that the FDA sees the unmet need and will engage closely. It does not tell us whether the drug preserves insulin production. The real tests are the Phase 2b readout in the second half of 2027 and the safety data that come with it. Small biotech companies often use designations to signal progress to investors and partners, so readers should look for numbers rather than headlines.
What to watch after the SAB-142 FDA Fast Track designation
- Completion of SAFEGUARD enrolment in the fourth quarter of 2026.
- Topline data in the second half of 2027.
- Progress of the investigator-led PRISE-hATG trial.
- Safety and immune effects reported in patients.
Frequently asked questions about the SAB-142 FDA Fast Track designation
What is the SAB-142 FDA Fast Track designation?
An FDA status meant to facilitate development and review of drugs for serious conditions with unmet needs. SAB-142 received it for new-onset Stage 3 type 1 diabetes.
Does the SAB-142 FDA Fast Track designation mean approval?
No. It is experimental and in clinical trials.
What is SAB-142?
A fully human anti-thymocyte immunoglobulin made in transchromosomic cattle, intended to modify the immune attack in type 1 diabetes.
When will trial results arrive?
The company expects topline data from its Phase 2b SAFEGUARD trial in the second half of 2027.
Does it cure type 1 diabetes?
No. The aim is to slow the loss of insulin-producing cells, and efficacy has not been shown.
How we reported this: we relied on SAB Biotherapeutics’ 13 October 2026 announcement, which is a company statement. Last updated: 14 October 2026. This article is news reporting and not medical advice.
